Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187127 | 0.91 | CA1 (0.58) | APPCA1CA2CA7CA9 | |
| SCHEMBL31403396 | 0.89 | CA1 (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL30998827 | 0.89 | CA1 (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL30998823 | 0.89 | CA1 (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL30998834 | 0.89 | CA1 (0.55) | APPCA1CA2CA7CA9 | |
| SCHEMBL4552830 | 0.84 | LTA4H (0.54) | APPCA1CA2CA7CA9 | |
| SCHEMBL709673 | 0.84 | APP (0.63) | APPCA1CA2CA7CA9 | |
| 1,4-Dimethoxybenzene SCHEMBL4957328 | 0.81 | CA1 (0.73) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10370252 | 0.79 | PKM (0.47) | APPCA1CA2CA7CA9 | |
| SCHEMBL2601885 | 0.79 | RELA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | THE PROCTER &GAMBLE COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-6696456-B1 | CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-02-24 | — | — | US | disclosed |
| EP-1224171-A1 | BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027084-A1 | BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | ADAM17, ADAM9, SI | APP 597/4885CA1 493/4885CA2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.